![](/img/cover-not-exists.png)
E34Analysis of clinical outcomes according to mutation subtype in EGFR-positive advanced non-small cell lung cancer (aNSCLC) patients treated with EGFR Tyrosine Kinases Inhibitors (TKIs) as first line
Veccia, A, Girlando, S, Dipasquale, M, Barbareschi, M, Caffo, OVolume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx426.033
Date:
October, 2017
File:
PDF, 49 KB
english, 2017